VolitionRx (VNRX) Competitors $0.79 +0.04 (+5.12%) As of 07/3/2025 03:36 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock VNRX vs. RZLT, UPXI, TERN, ARCT, CMPX, ATXS, SNDL, GOSS, MBX, and AQSTShould you be buying VolitionRx stock or one of its competitors? The main competitors of VolitionRx include Rezolute (RZLT), Upexi (UPXI), Terns Pharmaceuticals (TERN), Arcturus Therapeutics (ARCT), Compass Therapeutics (CMPX), Astria Therapeutics (ATXS), SNDL (SNDL), Gossamer Bio (GOSS), MBX Biosciences (MBX), and Aquestive Therapeutics (AQST). These companies are all part of the "pharmaceutical products" industry. VolitionRx vs. Its Competitors Rezolute Upexi Terns Pharmaceuticals Arcturus Therapeutics Compass Therapeutics Astria Therapeutics SNDL Gossamer Bio MBX Biosciences Aquestive Therapeutics Rezolute (NASDAQ:RZLT) and VolitionRx (NYSE:VNRX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership. Do insiders and institutionals hold more shares of RZLT or VNRX? 83.0% of Rezolute shares are owned by institutional investors. Comparatively, 8.1% of VolitionRx shares are owned by institutional investors. 18.4% of Rezolute shares are owned by company insiders. Comparatively, 10.4% of VolitionRx shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Is RZLT or VNRX more profitable? Rezolute has a net margin of 0.00% compared to VolitionRx's net margin of -2,321.14%. VolitionRx's return on equity of 0.00% beat Rezolute's return on equity.Company Net Margins Return on Equity Return on Assets RezoluteN/A -70.09% -63.08% VolitionRx -2,321.14%N/A -163.39% Do analysts rate RZLT or VNRX? Rezolute currently has a consensus price target of $11.83, suggesting a potential upside of 147.82%. VolitionRx has a consensus price target of $3.50, suggesting a potential upside of 343.04%. Given VolitionRx's higher probable upside, analysts plainly believe VolitionRx is more favorable than Rezolute.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rezolute 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14VolitionRx 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.00 Does the media favor RZLT or VNRX? In the previous week, Rezolute's average media sentiment score of 1.87 beat VolitionRx's score of 0.00 indicating that Rezolute is being referred to more favorably in the media. Company Overall Sentiment Rezolute Very Positive VolitionRx Neutral Which has more volatility and risk, RZLT or VNRX? Rezolute has a beta of 1.03, indicating that its stock price is 3% more volatile than the S&P 500. Comparatively, VolitionRx has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500. Which has better valuation and earnings, RZLT or VNRX? VolitionRx has higher revenue and earnings than Rezolute. Rezolute is trading at a lower price-to-earnings ratio than VolitionRx, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRezoluteN/AN/A-$68.46M-$1.15-4.15VolitionRx$1.31M62.21-$35.32M-$0.27-2.93 SummaryRezolute and VolitionRx tied by winning 7 of the 14 factors compared between the two stocks. Get VolitionRx News Delivered to You Automatically Sign up to receive the latest news and ratings for VNRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VNRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VNRX vs. The Competition Export to ExcelMetricVolitionRxDiagnostic substances IndustryMedical SectorNYSE ExchangeMarket Cap$81.39M$17.11M$5.53B$20.72BDividend YieldN/AN/A5.24%3.72%P/E Ratio-2.19N/A27.5228.09Price / Sales62.2116.32421.0238.30Price / CashN/AN/A36.8922.53Price / Book-7.180.028.044.58Net Income-$35.32M-$15.61M$3.18B$986.06M7 Day Performance-5.69%-7.39%2.90%2.79%1 Month Performance36.92%4.52%3.70%5.46%1 Year Performance27.42%-33.03%36.15%15.06% VolitionRx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VNRXVolitionRx1.6975 of 5 stars$0.79+5.1%$3.50+343.0%+22.5%$81.39M$1.31M-2.1980RZLTRezolute3.0877 of 5 stars$4.03-1.9%$11.83+193.6%+14.5%$351.48MN/A-3.5040Positive NewsUPXIUpexi3.3003 of 5 stars$10.00+8.1%$16.00+60.0%-60.0%$350.72M$26M0.00130Upcoming EarningsGap UpTERNTerns Pharmaceuticals3.9465 of 5 stars$3.68-5.6%$15.63+324.6%-38.3%$340.61MN/A-3.3840ARCTArcturus Therapeutics3.7849 of 5 stars$12.51+1.8%$53.50+327.7%-37.8%$333.31M$152.31M-4.94180News CoveragePositive NewsAnalyst ForecastCMPXCompass Therapeutics3.2555 of 5 stars$2.54+5.8%$13.13+416.7%+238.4%$331.88M$850K-6.2020Analyst UpgradeATXSAstria Therapeutics1.941 of 5 stars$5.61-4.3%$30.00+434.8%-35.4%$330.70MN/A-3.0030News CoverageSNDLSNDL3.6663 of 5 stars$1.24-0.8%$3.63+192.3%-34.9%$328.47M$671.81M-4.282,516News CoveragePositive NewsGOSSGossamer Bio3.7798 of 5 stars$1.37-4.9%$7.75+465.7%+18.9%$327.32M$114.70M-5.96180MBXMBX Biosciences3.1218 of 5 stars$9.73-0.1%$37.50+285.4%N/A$325.22MN/A0.0036AQSTAquestive Therapeutics1.5509 of 5 stars$3.29+1.2%$10.14+208.3%+54.4%$322.82M$57.56M-5.58160News Coverage Related Companies and Tools Related Companies RZLT Alternatives UPXI Alternatives TERN Alternatives ARCT Alternatives CMPX Alternatives ATXS Alternatives SNDL Alternatives GOSS Alternatives MBX Alternatives AQST Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:VNRX) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredThe mainstream media is wrong about AI — againThe mainstream media got it wrong … yet again. AI has recently turned the tech world on its head. And th...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VolitionRx Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share VolitionRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
